BR112018005499A2 - métodos de tratamento de pressão intraocular com ativadores de tie-2. - Google Patents
métodos de tratamento de pressão intraocular com ativadores de tie-2.Info
- Publication number
- BR112018005499A2 BR112018005499A2 BR112018005499A BR112018005499A BR112018005499A2 BR 112018005499 A2 BR112018005499 A2 BR 112018005499A2 BR 112018005499 A BR112018005499 A BR 112018005499A BR 112018005499 A BR112018005499 A BR 112018005499A BR 112018005499 A2 BR112018005499 A2 BR 112018005499A2
- Authority
- BR
- Brazil
- Prior art keywords
- activators
- tie
- methods
- intraocular pressure
- treating intraocular
- Prior art date
Links
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 230000004410 intraocular pressure Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222481P | 2015-09-23 | 2015-09-23 | |
| PCT/US2016/053107 WO2017053566A1 (en) | 2015-09-23 | 2016-09-22 | Methods of treating intraocular pressure with activators of tie-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018005499A2 true BR112018005499A2 (pt) | 2018-10-09 |
Family
ID=58276474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018005499A BR112018005499A2 (pt) | 2015-09-23 | 2016-09-22 | métodos de tratamento de pressão intraocular com ativadores de tie-2. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10952992B2 (enExample) |
| EP (3) | EP3352856B1 (enExample) |
| JP (3) | JP6959924B2 (enExample) |
| KR (1) | KR20180054677A (enExample) |
| CN (2) | CN113713101B (enExample) |
| AU (2) | AU2016326510C1 (enExample) |
| BR (1) | BR112018005499A2 (enExample) |
| CA (1) | CA2998673C (enExample) |
| ES (2) | ES2894802T3 (enExample) |
| IL (1) | IL258150B (enExample) |
| MX (2) | MX387804B (enExample) |
| MY (1) | MY194736A (enExample) |
| PH (1) | PH12018500658A1 (enExample) |
| SG (1) | SG10201912000WA (enExample) |
| WO (1) | WO2017053566A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| MY194736A (en) | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
| WO2020012444A1 (en) * | 2018-07-13 | 2020-01-16 | Susan Quaggin | Ve-ptp inhibition in glaucoma |
| CN114072205A (zh) * | 2019-04-18 | 2022-02-18 | 视点制药公司 | 用tie-2激活剂治疗高血压的方法 |
| US11253502B2 (en) | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
| GB2589400A (en) * | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| AU2020376807A1 (en) | 2019-10-29 | 2022-05-19 | EyePoint Pharmaceuticals, Inc. | Small molecule activators of Tie-2 |
| EP4087565A1 (en) * | 2020-01-08 | 2022-11-16 | EyePoint Pharmaceuticals, Inc. | Combinations of tie-2 activators and prostaglandins and uses thereof |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US645503A (en) | 1899-05-11 | 1900-03-13 | Timothy Francis Crowley | Cutter-gage for ice-cream, & c. |
| US953924A (en) | 1909-06-28 | 1910-04-05 | Dow Wire & Iron Works | Sliding door. |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| WO1998018914A1 (en) | 1996-10-31 | 1998-05-07 | Duke University | Soluble tie2 receptor |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| JP2002540165A (ja) | 1999-03-26 | 2002-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｉｅ２レセプターアクチベーターによる血管透過性の調節 |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| US6897201B2 (en) * | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
| AU2002335085A1 (en) | 2001-10-25 | 2003-05-06 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| AU2003229627A1 (en) | 2002-04-08 | 2003-10-20 | Max-Planck-Gesellschaft Zur | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| JP2006501147A (ja) | 2002-04-25 | 2006-01-12 | ユニバーシティー オブ コネティカット ヘルス センター | 非ワクチン治療法の治療効果を改善するための熱ショックタンパク質の使用 |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| LT2653465T (lt) | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| WO2006014729A2 (en) | 2004-07-20 | 2006-02-09 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| EP2457578B1 (en) | 2004-09-28 | 2015-08-19 | Aprogen, Inc. | Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction |
| KR101017301B1 (ko) | 2004-12-21 | 2011-02-28 | 메드임뮨 리미티드 | 앤지오포이에틴-2에 대한 항체 및 그의 용도 |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| EP3168234A1 (en) | 2005-12-15 | 2017-05-17 | Medimmune Limited | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| ES2643469T3 (es) | 2006-04-07 | 2017-11-23 | Aerpio Therapeutics, Inc. | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos |
| DE102006016426A1 (de) * | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP2076290B1 (en) | 2006-10-27 | 2016-12-14 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| WO2009105774A2 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| BRPI1006898A2 (pt) | 2009-01-12 | 2015-09-08 | Akebia Therapeutics Inc | métodos de tratamento da síndrome do extravasamento vascular. |
| WO2010097800A1 (en) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| KR20110130454A (ko) | 2009-03-03 | 2011-12-05 | 알콘 리서치, 리미티드 | 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물 |
| WO2010101971A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| MY160399A (en) | 2009-07-06 | 2017-03-15 | Aerpio Therapeutics Inc | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2012009288A2 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| US20120129847A1 (en) | 2010-10-07 | 2012-05-24 | Kevin Gene Peters | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| EP2647385A4 (en) | 2010-12-02 | 2014-04-30 | Maruzen Pharm Co Ltd | TIE2 ACTIVATOR, VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF), ANTI-ANGIOGENESIS AGENT, MEANS FOR REINFORCING BLOOD VESSELS, MEANS FOR THE NORMALIZATION OF BLOOD VESSELS, DEVICES FOR STABILIZING BLOOD VESSELS AND PHARMACEUTICAL COMPOSITION |
| ES2774972T3 (es) | 2011-10-13 | 2020-07-23 | Aerpio Therapeutics Inc | Tratamiento de enfermedades oculares |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| EP2836232A4 (en) | 2012-04-13 | 2016-03-16 | Univ Johns Hopkins | TREATMENT OF ISCHEMIC RETINOPATHY |
| MX361337B (es) | 2012-07-13 | 2018-12-04 | Roche Glycart Ag | Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares. |
| HRP20181124T1 (hr) | 2012-07-31 | 2018-11-02 | The Board Of Regents Of The University Of Texas System | Postupci i pripravci za in vivo indukciju nastajanja beta stanica gušterače |
| ES2959385T3 (es) | 2012-10-11 | 2024-02-26 | Ascendis Pharma Ophthalmology Div A/S | Profármacos neutralizantes de VEGF que comprenden ranibizumab para el tratamiento de afecciones oculares caracterizadas por neovascularización ocular |
| ES3023054T3 (en) | 2012-11-08 | 2025-05-29 | Clearside Biomedical Inc | Methods for the treatment of ocular disease in human subjects |
| WO2014079709A1 (en) | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| GB2516561B (en) * | 2013-03-15 | 2016-03-09 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US10314882B2 (en) | 2013-04-11 | 2019-06-11 | Sunnybrook Research Institute | Methods, uses and compositions of Tie2 agonists |
| EP3010525A1 (en) | 2013-06-20 | 2016-04-27 | Novartis AG | Use of a vegf antagonist in treating choroidal neovascularisation |
| WO2014203183A1 (en) | 2013-06-20 | 2014-12-24 | Novartis Ag | Use of a vegf antagonist in treating macular edema |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| WO2015004616A1 (en) | 2013-07-11 | 2015-01-15 | Novartis Ag | Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients |
| KR20160030504A (ko) | 2013-07-11 | 2016-03-18 | 노파르티스 아게 | 미숙아 망막병증의 치료에 있어서 vegf 길항제의 용도 |
| US9902767B2 (en) | 2013-07-29 | 2018-02-27 | Samsung Electronics Co., Ltd. | Method of blocking vascular leakage using an anti-ANG2 antibody |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| CN105765385B (zh) | 2013-10-01 | 2019-02-01 | 斯弗因高泰克有限公司 | 预测出现主要不良心脏事件的风险的方法 |
| HUE044660T2 (hu) | 2013-11-01 | 2019-11-28 | Regeneron Pharma | Angiopoietin-alapú beavatkozások cerebrális malária kezelésére |
| CN106456614A (zh) | 2014-03-14 | 2017-02-22 | 爱尔皮奥治疗有限公司 | HPTP‑β抑制剂 |
| JP2015199733A (ja) * | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
| JP6603653B2 (ja) | 2014-04-04 | 2019-11-06 | 株式会社ダイゾー | 吐出容器 |
| US9719135B2 (en) * | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
| WO2016049183A1 (en) | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MY194736A (en) * | 2015-09-23 | 2022-12-15 | Aerpio Therapeutics Inc | Methods of treating intraocular pressure with activators of tie-2 |
| US11253502B2 (en) * | 2019-04-29 | 2022-02-22 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the Schlemm's canal |
-
2016
- 2016-09-22 MY MYPI2018000423A patent/MY194736A/en unknown
- 2016-09-22 JP JP2018534502A patent/JP6959924B2/ja active Active
- 2016-09-22 ES ES16849594T patent/ES2894802T3/es active Active
- 2016-09-22 CN CN202110932276.3A patent/CN113713101B/zh active Active
- 2016-09-22 EP EP16849594.3A patent/EP3352856B1/en active Active
- 2016-09-22 EP EP21191499.9A patent/EP3977994B1/en active Active
- 2016-09-22 BR BR112018005499A patent/BR112018005499A2/pt not_active Application Discontinuation
- 2016-09-22 CA CA2998673A patent/CA2998673C/en active Active
- 2016-09-22 AU AU2016326510A patent/AU2016326510C1/en active Active
- 2016-09-22 US US15/273,068 patent/US10952992B2/en active Active
- 2016-09-22 EP EP24169519.6A patent/EP4414032A3/en active Pending
- 2016-09-22 SG SG10201912000WA patent/SG10201912000WA/en unknown
- 2016-09-22 KR KR1020187010228A patent/KR20180054677A/ko not_active Withdrawn
- 2016-09-22 ES ES21191499T patent/ES2981607T3/es active Active
- 2016-09-22 CN CN201680068508.2A patent/CN108290057A/zh active Pending
- 2016-09-22 WO PCT/US2016/053107 patent/WO2017053566A1/en not_active Ceased
- 2016-09-22 MX MX2018003542A patent/MX387804B/es unknown
-
2018
- 2018-03-15 IL IL258150A patent/IL258150B/en active IP Right Grant
- 2018-03-22 MX MX2021010915A patent/MX2021010915A/es unknown
- 2018-03-23 PH PH12018500658A patent/PH12018500658A1/en unknown
-
2021
- 2021-01-15 US US17/150,430 patent/US11666558B2/en active Active
- 2021-10-08 JP JP2021165943A patent/JP7451472B2/ja active Active
-
2022
- 2022-04-20 AU AU2022202618A patent/AU2022202618B2/en active Active
-
2023
- 2023-04-21 US US18/304,511 patent/US12171751B2/en active Active
-
2024
- 2024-03-06 JP JP2024033979A patent/JP2024061772A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018005499A2 (pt) | métodos de tratamento de pressão intraocular com ativadores de tie-2. | |
| EP3340923A4 (en) | Venous valve prosthesis | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| EP3352838C0 (en) | PRIMING DEVICE | |
| DK3230463T4 (da) | Hurtig Forbehandling | |
| PT3265087T (pt) | Método de tratamento com tradipitant | |
| DE112014006223A5 (de) | CVT-Antriebsstrang | |
| BR112016018754A2 (pt) | método de tratamento de um câncer com vascularização | |
| BR112018000204A2 (pt) | métodos de tratamento de colite | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| BR112016019822A2 (pt) | Determinação enzimática de hba1c | |
| EP3583223A4 (en) | HIGH PRESSURE ZONE TRAINING FOR PRETREATMENT | |
| SI3368044T1 (sl) | Zdravljenje oligoovulacije, povezane s steatozo jeter | |
| EP3724710C0 (de) | Process-scope | |
| DE112015001600A5 (de) | CVT-Antriebsstrang | |
| DK3445722T3 (da) | Pef-kammer | |
| IL270867A (en) | Treatment method | |
| EP3697821A4 (en) | PROCEDURE | |
| DE112016005703A5 (de) | Stufenlosgetriebe | |
| EP3736524C0 (de) | Api-projektil und entsprechendes herstellverfahren | |
| ES1149884Y (es) | Calzado luminoso | |
| ES2661264T8 (es) | Tratamiento de superficies curvadas | |
| PL3197664T3 (pl) | Sposób rozdmuchiwania z rozciąganiem | |
| DE112017003989A5 (de) | CVT-Antriebsstrang | |
| EP3284795A4 (en) | NUCLEAR ACTIVATOR WITH FREEZER PROTECTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |